Citations Appearing in 2016

  1. Aitken, S.L., J. Zhou, S.S. Ghantoji, D.P. Kontoyiannis, R.B. Jones, V.H. Tam and R.F. Chemaly. Pharmacokinetics and safety of intravesicular cidofovir in allogeneic HSCT recipients. Journal of Antimicrobial Chemotherapy 71(3): 727-730, 2016.
  2. Anderson, P.O. and J.B. Sauberan. Modeling drug passage into human milk. Clinical Pharmacology & Therapeutics 100(1): 42-52, 2016.
  3. Bergen, P.J., J.B. Bulitta, C.M.J. Kirkpatrick, K.E. Rogers, M.J. McGregor, S.C. Wallis, . . .and C.B. Landersdorfer. Effect of different renal function on antibacterial effects of piperacillin against Pseudomonas aeruginosa evaluated via the hollow-fibre infection model and mechanism-based modelling. Journal of Antimicrobial Chemotherapy 17(9): 2509-2520, 2016.
  4. Bi, Y., J. Deng, D. Murry and G. An. A Whole-Body Physiologically Based Pharmacokinetic Model of Gefitinib in Mice and Scale-Up to Humans. The AAPS Journal 18(1): 228-238, 2016.
  5. Bonate, P.L., A. Desai, A. Rizwan, Z. Lu and S. Tannenbaum (2016). Nonlinear Mixed Effects Modeling in Systems Pharmacology. Systems Pharmacology and Pharmacodynamics. D. E. Mager and H. H. C. Kimko. Cham, Springer International Publishing: 255-276.
  6. Brenner, M.C., W. Krzyzanski, J.Z. Chou, P.E. Signore, C.K. Fung, D. Guzman, . . .and K.E. Lipson. FG-3019, a Human Monoclonal Antibody Recognizing Connective Tissue Growth Factor, is Subject to Target-Mediated Drug Disposition. Pharmaceutical Research 33(367): 1-17, 2016.
  7. Britt, N.S., N. Patel, R.T. Horvat and M.E. Steed. Vancomycin 24-Hour Area under the Curve/Minimum Bactericidal Concentration Ratio as a Novel Predictor of Mortality in Methicillin-Resistant Staphylococcus aureus Bacteremia. Antimicrobial Agents and Chemotherapy 60(5): 3070-3075, 2016.
  8. Buitrago, E., U. Winter, G. Williams, M. Asprea, G. Chantada and P. Schaiquevich. Pharmacokinetics of Melphalan After Intravitreal Injection in a Rabbit Model. Journal of Ocular Pharmacology and Therapeutics 32(4): 230-235, 2016.
  9. Bulik, C.C., Ó.O. Okusanya, E.A. Lakota, A. Forrest, S.M. Bhavnani, J.L. Hoover, . . .and P.G. Ambrose. Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin Against Gram-Positive Organisms Using Data From Murine Infection Models. Antimicrobial Agents and Chemotherapy 61(12), 2016.
  10. Bustinduy, A.L., D. Waterhouse, J.C. de Sousa-Figueiredo, S.A. Roberts, A. Atuhaire, G.J. Van Dam, . . .and J.R. Stothard. Population Pharmacokinetics and Pharmacodynamics of Praziquantel in Ugandan Children with Intestinal Schistosomiasis: Higher Dosages Are Required for Maximal Efficacy. mBio 7(4), 2016.
  11. Cai, Y., T.-P. Lim, J. Teo, S. Sasikala, E.C.Y. Chan, Y.J. Hong, . . .and A.L. Kwa. Evaluating polymyxin B-based combinations against carbapenem-resistant Escherichia coli in time-kill studies and in a hollow-fiber infection model. Antimicrobial Agents and Chemotherapy 61(1), 2016.
  12. Cai, Y., T.-P. Lim, J. Teo, S. Sasikala, W. Lee, Y. Hong, . . .and A.L. Kwa. In vitro Activity of Polymyxin B in Combination with Various Antibiotics against Extensively-Drug Resistant Enterobacter cloacae with Decreased Susceptibility to Polymyxin B. Antimicrobial Agents and Chemotherapy 20(9): 5238-5264, 2016.
  13. Cheah, S.-E., J. Li, B.T. Tsuji, A. Forrest, J.B. Bulitta and R.L. Nation. Colistin and polymyxin B dosage regimens against Acinetobacter baumannii: Differences in activity and the emergence of resistance. Antimicrobial Agents and Chemotherapy 60(7): 3921-3933, 2016.
  14. Cvijanovich, N.Z., J.C. King, H.R. Flori, G. Gildengorin, A.A. Vinks and H.R. Wong. A Safety and Dose Escalation Study of Intravenous Zinc Supplementation in Pediatric Critical Illness. Journal of Parenteral and Enteral Nutrition 40(6): 860-868, 2016.
  15. Deci, M.B., S.W. Ferguson, M. Liu, D.C. Peterson, S.P. Koduvayur and J. Nguyen. Utilizing clathrin triskelions as carriers for spatially controlled multi-protein display. Biomaterials 108: 120-128, 2016.
  16. Deshpande, D., J.G. Pasipanodya and T. Gumbo. Azithromycin Dose To Maximize Efficacy and Suppress Acquired Drug Resistance in Pulmonary Mycobacterium avium Disease. Antimicrobial Agents and Chemotherapy 60(4): 2157-2163, 2016.
  17. Deshpande, D., S. Srivastava, S. Musuka and T. Gumbo. Thioridazine as Chemotherapy For Mycobacterium avium Complex Diseases. Antimicrobial Agents and Chemotherapy 60(8): 4652-4658, 2016.
  18. RAMÍREZ, M.A., E. PIANI, C. LINDT, C. PRESA ROSSA, E. CABAÑA, E. BARONI, N. RUSSI, E. FORMENTIN. Activity of marbofloxacin against Escherichia coli in the presence of serum of water buffalo (Bubalus bubalis). Revuede Medecine Veterinaire 5(6): 159-168, 2016.
  19. Edson, K.Z., B.M. Wu, A. Iyer, W. Goodman, G.L. Skiles and R. Subramanian. Determination of Etelcalcetide Biotransformation and Hemodialysis Kinetics to Guide the Timing of Its Dosing. Kidney International Reports 1(1): 24-33, 2016.
  20. Ferro, B.E., S. Srivastava, D. Deshpande, J.G. Pasipanodya, D. van Soolingen, J.W. Mouton, . . .and T. Gumbo. Moxifloxacin’s Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease. Antimicrobial Agents and Chemotherapy 60(6): 3779-3785, 2016.
  21. . Tigecycline Is Highly Efficacious against Mycobacterium abscessus Pulmonary Disease. Antimicrobial Agents and Chemotherapy 60(5): 2895-2900, 2016.
  22. Fong, W.-K., T.L. Hanley, B. Thierry, A. Hawley, B.J. Boyd and C.B. Landersdorfer. External manipulation of nanostructure in photoresponsive lipid depot matrix to control and predict drug release in vivo. Journal of Controlled Release 228: 67-73, 2016.
  23. Galjndo Bedor, D.C., S. Marchand, I. Lamarche, J. Laroche, D. Pereira de Santana and W. Couet. Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats: 5. Oseltamivir carboxylate. Antimicrobial Agents and Chemotherapy 60(8): 5085-5087, 2016.
  24. Gallegos, K.M., G.L. Drusano, D.Z. D′Argenio and A.N. Brown. Chikungunya Virus: In Vitro Response to Combination Therapy With Ribavirin and Interferon Alfa 2a. Journal of Infectious Diseases 214(8): 1192-1197, 2016.
  25. Gaspar, M.C., N. Grégoire, J.J.S. Sousa, A.A.C.C. Pais, I. Lamarche, P. Gobin, . . .and W. Couet. Pulmonary pharmacokinetics of levofloxacin in rats after aerosolization of immediate-release chitosan or sustained-release PLGA microspheres. European Journal of Pharmaceutical Sciences 93: 184-191, 2016.
  26. Glassman, P.M. and J.P. Balthasar. Application of a catenary PBPK model to predict the disposition of “catch and release” anti-PCSK9 antibodies. International Journal of Pharmaceutics 505(1–2): 69-78, 2016.
  27. . Physiologically-based modeling to predict the clinical behavior of monoclonal antibodies directed against lymphocyte antigens. mAbs 9(2): 297-306, 2016.
  28. . Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies. Journal of Pharmacokinetics and Pharmacodynamics 43(4): 427-446, 2016.
  29. Golasik, M., M. Herman, M. Olbert, T. Librowski, J. Szklarzewicz and W. Piekoszewski. Toxicokinetics and tissue distribution of titanium in ionic form after intravenous and oral administration. Toxicology Letters 247: 56-61, 2016.
  30. Golob, S., M. Perry, M. Lusi, M.R. Chierotti, I. Grabnar, L. Lassiani, . . .and M.J. Zaworotko. Improving Biopharmaceutical Properties of Vinpocetine Through Cocrystallization. Journal of Pharmaceutical Sciences 105(12): 3626-3633, 2016.
  31. Hall, R.G., J.G. Pasipanodya, C. Meek, R.D. Leff, M. Swancutt and T. Gumbo. Fractal Geometry-Based Decrease in Trimethoprim-Sulfamethoxazole Concentrations in Overweight and Obese People. CPT: Pharmacometrics & Systems Pharmacology 5(12): 674-681, 2016.
  32. Jacobs, M., N. Grégoire, W. Couet and J.B. Bulitta. Distinguishing Antimicrobial Models with Different Resistance Mechanisms via Population Pharmacodynamic Modeling. PLoS Comput Biol 12(3): e1004782, 2016.
  33. Jiang, X.-L., H.-W. Shen, D.E. Mager, S. Schmidt and A.-M. Yu. Development of a mechanism-based pharmacokinetic/pharmacodynamic model to characterize the thermoregulatory effects of serotonergic drugs in mice. Acta Pharmaceutica Sinica B 6(5): 492-503, 2016.
  34. Johnson, R.J., C.L. Kerr, S.S. Enouri, P. Modi, B.D.X. Lascelles and J.R.E. del Castillo. Pharmacokinetics of liposomal encapsulated buprenorphine suspension following subcutaneous administration to cats. Journal of Veterinary Pharmacology and Therapeutics 40(3): 256-269, 2016.
  35. Kim, T.H., S. Shin, J.B. Bulitta, Y.S. Youn, S.D. Yoo and B.S. Shin. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro–in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation. Molecular Pharmaceutics 14(1): 53-65, 2016.
  36. Kovanda, L.L., R. Petraitiene, V. Petraitis, T.J. Walsh, A. Desai, P. Bonate and W.W. Hope. Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints. Journal of Antimicrobial Chemotherapy 71(7): 1885-1891, 2016.
  37. Krzyzanski, W., J.J. Xiao, B. Sasu, B. Hinkle and J.J. Perez-Ruixo. Pharmacodynamic Model of Hepcidin Regulation of Iron Homeostasis in Cynomolgus Monkeys. The AAPS Journal 18(3): 713-727, 2016.
  38. Landersdorfer, C.B., R.L. Findling, J.A. Frazier, V. Kafantaris and C.M.J. Kirkpatrick. Lithium in Paediatric Patients with Bipolar Disorder: Implications for Selection of Dosage Regimens via Population Pharmacokinetics/Pharmacodynamics. Clinical Pharmacokinetics 56(1): 77-90, 2016.
  39. Landersdorfer, C.B., T.-H. Nguyen, L.T. Lieu, G. Nguyen, R.J. Bischof, E.N. Meeusen, . . .and M.P. McIntosh. Substantial targeting advantage achieved by pulmonary administration of colistin methanesulfonate: Insights from a large animal model. Antimicrobial Agents and Chemotherapy 61(1), 2016.
  40. Lee, B.-y., K.-i. Kwon, M.-S. Kim and I.-h. Baek. Michaelis–Menten elimination kinetics of etanercept, rheumatoid arthritis biologics, after intravenous and subcutaneous administration in rats. European Journal of Drug Metabolism and Pharmacokinetics 41(4): 433-439, 2016.
  41. Lee, H.Y., A. Marahatta, B. Bhandary, H.-R. Kim and H.-J. Chae. 4-Phenylbutyric acid regulates CCl4-induced acute hepatic dyslipidemia in a mouse model: A mechanism-based PK/PD study. European Journal of Pharmacology 777: 104-112, 2016.
  42. Lenhard, J.R., J.B. Bulitta, T.D. Connell, N. King-Lyons, C.B. Landersdorfer, S.-E. Cheah, . . .and B.T. Tsuji. High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii. Journal of Antimicrobial Chemotherapy 72(1): 153-165, 2016.
  43. Lestner, J.M., A.H. Groll, G. Aljayyoussi, N.L. Seibel, A. Shad, C. Gonzalez, . . .and W.W. Hope. Population Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Children. Antimicrobial Agents and Chemotherapy 60(12): 7340-7346, 2016.
  44. Li, Y., M. Monine, Y. Huang, P. Swann, I. Nestorov and Y. Lyubarskaya. Quantitation and pharmacokinetic modeling of therapeutic antibody quality attributes in human studies. mAbs 8: 1-9, 2016.
  45. Liang, X., H. Wang, Y. Zhu, R. Zhang, V.C. Cogger, X. Liu, . . .and M.S. Roberts. Short- and Long-Term Tracking of Anionic Ultrasmall Nanoparticles in Kidney. ACS Nano 10(1): 387-395, 2016.
  46. Liu, D., H. Yang, J. Jiang, P. Nagy, K. Shen, J. Qian and P. Hu. Pharmacokinetic and Pharmacodynamic Modeling Analysis of Intravenous Esomeprazole in Healthy Volunteers. The Journal of Clinical Pharmacology 56(7): 816-826, 2016.
  47. Liu, X. and Y. Wang. Comparing the performance of FOCE and different expectation-maximization methods in handling complex population physiologically-based pharmacokinetic models. Journal of Pharmacokinetics and Pharmacodynamics 43(4): 359-370, 2016.
  48. Ly, N.S., Z.P. Bulman, J.B. Bulitta, C. Baron, G.G. Rao, P.N. Holden, . . .and B.T. Tsuji. Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 60(5): 2870-2880, 2016.
  49. Machuca, J., M. Ortiz, E. Recacha, P. Díaz-De-Alba, F. Docobo-Perez, J.-M. Rodríguez-Martínez and Á. Pascual. Impact of AAC(6′)-Ib-cr in combination with chromosomal-mediated mechanisms on clinical quinolone resistance in Escherichia coli. Journal of Antimicrobial Chemotherapy 71(11): 3066-3071, 2016.
  50. Mahmood, I. and C.-M. Staschen. Prediction of Human Glomerular Filtration Rate from Preterm Neonates to Adults: Evaluation of Predictive Performance of Several Empirical Models. The AAPS Journal 18(2): 445-454, 2016.
  51. Manchandani, P., Y. Dubrovskaya, S. Gao and V.H. Tam. Comparative Pharmacokinetic Profiling of Different Polymyxin B Components. Antimicrobial Agents and Chemotherapy 60(11): 6980-6982, 2016.
  52. Marchand, S., N. Grégoire, J. Brillault, I. Lamarche, P. Gobin and W. Couet. Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats. 4. Aztreonam. Antimicrobial Agents and Chemotherapy 60(5): 3196-3198, 2016.
  53. Miao, X., G. Koch, S. Ait-Oudhia, R.M. Straubinger and W.J. Jusko. Pharmacodynamic Modeling of Cell Cycle Effects for Gemcitabine and Trabectedin Combinations in Pancreatic Cancer Cells. Frontiers in Pharmacology 7: 421, 2016.
  54. Miao, X., G. Koch, R. Straubinger and W. Jusko. Pharmacodynamic modeling of combined chemotherapeutic effects predicts synergistic activity of gemcitabine and trabectedin in pancreatic cancer cells. Cancer Chemotherapy and Pharmacology 77(1): 1-13, 2016.
  55. Ng, C.M., P.J. Fielder, J. Jin and R. Deng. Mechanism-Based Competitive Binding Model to Investigate the Effect of Neonatal Fc Receptor Binding Affinity on the Pharmacokinetic of Humanized Anti-VEGF Monoclonal IgG1 Antibody in Cynomolgus Monkey. The AAPS Journal 18(4): 948-959, 2016.
  56. Noh, K., S. Chen, Q.J. Yang and K.S. Pang. Physiologically-Based Pharmacokinetic Modeling Revealed Minimal Codeine Intestinal Metabolism in First-Pass Removal in Rats. Biopharmaceutics & Drug Disposition 38(1): 50-74, 2016.
  57. Olivier, B., M. Swat and M. Moné (2016). Modeling and Simulation Tools: From Systems Biology to Systems Medicine. Systems Medicine. U. Schmitz and O. Wolkenhauer, Springer New York. 1386: 441-463.
  58. Phoenix, Timothy N., Deanna M. Patmore, S. Boop, N. Boulos, Megan O. Jacus, Yogesh T. Patel, . . .and Richard J. Gilbertson. Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype. Cancer Cell 29(4): 508-522, 2016.
  59. Rahbar, A.J., T.P. Lodise, P. Abraham, A. Lockwood, M.P. Pai, J. Patka, . . .and J. Salomone. Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients with Sepsis. Surgical Infections 17(6): 675-682, 2016.
  60. Ramos-Martín, V., A. Johnson, J. Livermore, L. McEntee, J. Goodwin, S. Whalley, . . .and W.W. Hope. Pharmacodynamics of vancomycin for CoNS infection: experimental basis for optimal use of vancomycin in neonates. Journal of Antimicrobial Chemotherapy 71(4): 992-1002, 2016.
  61. Rao, G.G., N.S. Ly, J.B. Bulitta, R.L. Soon, M.D. San Roman, P.N. Holden, . . .and B.T. Tsuji. Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategies. Journal of Antimicrobial Chemotherapy 71(11): 3148-3156, 2016.
  62. Rees, V.E., J.B. Bulitta, A. Oliver, B.T. Tsuji, C.R. Rayner, R.L. Nation and C.B. Landersdorfer. Resistance suppression by high-intensity, short-duration aminoglycoside exposure against hypermutable and non-hypermutable Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy 71(11): 3157-3167, 2016.
  63. Rodriguez, C.A., M. Agudelo, A.F. Zuluaga and O. Vesga. In vivo pharmacodynamics of piperacillin/tazobactam: implications for antimicrobial efficacy and resistance suppression with innovator and generic products. International Journal of Antimicrobial Agents 49(2): 189-197, 2016.
  64. Shi, J., H. Zheng, J. Yu, L. Zhu, T. Yan, P. Wu, . . .and Z. Liu. SGLT-1 Transport and Deglycosylation Inside Intestinal Cells are Key Steps in the Absorption and Disposition of Calycosin-7-O-β-D-Glucoside in Rats. Drug Metabolism and Disposition 44(3): 283-296, 2016.
  65. Siebert, N., C. Eger, D. Seidel, M. Jüttner, M. Zumpe, D. Wegner, . . .and H.N. Lode. Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2. mAbs 8(3): 604-616, 2016.
  66. Singh, A.P., K.F. Maass, A.M. Betts, K.D. Wittrup, C. Kulkarni, L.E. King, . . .and D.K. Shah. Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1). The AAPS Journal 18(4): 861-875, 2016.
  67. Singh, A.P., S. Sharma and D.K. Shah. Quantitative characterization of in vitro bystander effect of antibody-drug conjugates. Journal of Pharmacokinetics and Pharmacodynamics 43(6): 567-582, 2016.
  68. Srivastava, S., D. Deshpande, J. Pasipanodya, E. Nuermberger, S. Swaminathan and T. Gumbo. Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks. Clinical Infectious Diseases 63(3): S102-S109, 2016.
  69. Srivastava, S., C. Modongo, C.W. Siyambalapitiyage Dona, J.G. Pasipanodya, D. Deshpande and T. Gumbo. Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of Tuberculosis. Antimicrobial Agents and Chemotherapy 60(10): 5922-5927, 2016.
  70. Swaminathan, S., J.G. Pasipanodya, G. Ramachandran, A.K. Hemanth Kumar, S. Srivastava, D. Deshpande, . . .and T. Gumbo. Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests. Clinical Infectious Diseases 63(3): S63-S74, 2016.
  71. Tadken, T., M. Weiss, C. Modess, D. Wegner, T. Roustom, C. Neumeister, . . .and W. Siegmund. Trospium chloride is absorbed from two intestinal “absorption windows” with different permeability in healthy subjects. International Journal of Pharmaceutics 515(1–2): 367-373, 2016.
  72. Taich, P., M. Del Sole, F. Buontempo, G. Williams, U. Winter, M. Sgroi, . . .and P. Schaiquevich. Ocular topotecan pharmacokinetics following topical administration to rabbits for diffused anterior retinoblastoma. Journal of Pharmacy and Pharmacology 69(5): 574-581, 2016.
  73. Taich, P., M.A. Moretton, M.J. Del Sole, U. Winter, E. Bernabeu, J.O. Croxatto, . . .and P. Schaiquevich. Sustained-release hydrogels of topotecan for retinoblastoma. Colloids and Surfaces B: Biointerfaces 146: 624-631, 2016.
  74. Teramachi, J., R. Silbermann, P. Yang, W. Zhao, K.S. Mohammad, J. Guo, . . .and N. Kurihara. Blocking the ZZ domain of sequestosome1/p62 suppresses myeloma growth and osteoclast formation in vitro and induces dramatic bone formation in myeloma-bearing bones in vivo. Leukemia 30(2): 390-398, 2016.
  75. Thamlikitkul, V., Y. Dubrovskaya, P. Manchandani, T. Ngamprasertchai, A. Boonyasiri, J.T. Babic and V.H. Tam. Dosing and pharmacokinetics of polymyxin B in renal insufficiency. Antimicrobial Agents and Chemotherapy 61(1), 2016.
  76. Upton, R.N., D.J.R. Foster and A.Y. Abuhelwa. An introduction to physiologically-based pharmacokinetic models. Pediatric Anesthesia 26(11): 1036-1046, 2016.
  77. Weiss, M. Comparison of distributed and compartmental models of drug disposition: assessment of tissue uptake kinetics. Journal of Pharmacokinetics and Pharmacodynamics 43(5): 505-512, 2016.
  78. Weiss, M., A. Tura, A. Kautzky-Willer, G. Pacini and D.Z. D’Argenio. Human insulin dynamics in women: a physiologically based model. American Journal of Physiology – Regulatory, Integrative and Comparative Physiology 310(3): R568-574, 2016.
  79. Wetmore, C., V.M. Daryani, C.A. Billups, J.M. Boyett, S. Leary, R. Tanos, . . .and A. Gajjar. Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children’s Oncology Group Study ACNS1021. Cancer Medicine 5(7): 1416-1424, 2016.
  80. Wiederhold, N.P., L. Kovanda, L.K. Najvar, R. Bocanegra, M. Olivo, W.R. Kirkpatrick and T.F. Patterson. Isavuconazole is Effective for the Treatment of Experimental Cryptococcal Meningitis. Antimicrobial Agents and Chemotherapy 60(9): 5600-5603, 2016.
  81. Wittau, M., S. Paschke, M. Kurlbaum, J. Scheele, N.S. Ly, E. Hemper, . . .and J.B. Bulitta. Population Pharmacokinetics and Target Attainment of Ertapenem in Plasma and Tissue Assessed via Microdialysis in Morbidly Obese Patients after Laparoscopic Visceral Surgery. Antimicrobial Agents and Chemotherapy 61(1), 2016.
  82. Wyska, E., A. Świerczek, K. Pociecha and K. Przejczowska-Pomierny. Physiologically based modeling of lisofylline pharmacokinetics following intravenous administration in mice. European Journal of Drug Metabolism and Pharmacokinetics 41(4): 403-412, 2016.
  83. Yadav, R., J.B. Bulitta, R.L. Nation and C.B. Landersdorfer. Optimization of synergistic combination regimens against carbapenem- and aminoglycoside-resistant clinical Pseudomonas aeruginosa isolates via mechanism-based pharmacokinetic/pharmacodynamic modeling. Antimicrobial Agents and Chemotherapy 61(1), 2016.
  84. Yang, Q.J., J. Fan, S. Chen, L. Liu, H. Sun and K.S. Pang. Metabolite Kinetics: The Segregated Flow Model for Intestinal and Whole Body Physiologically Based Pharmacokinetic Modeling to Describe Intestinal and Hepatic Glucuronidation of Morphine in Rats In Vivo. Drug Metabolism and Disposition 44(7): 1123-1138, 2016.